A phase Ib/II trial in China reported that the oral PARP inhibitor HTMC0435 combined with temozolomide produced a manageable safety profile, a 25% response rate, and 11.2-month median overall survival in relapsed extensive-stage small-cell lung cancer (ID: 172ebf4786b3ffe3). The readout supports further exploration of PARP-chemotherapy combinations in difficult-to-treat SCLC. Separately, a review in Journal of Translational Medicine argues that ADC strategy is shifting from clinical promise to strategic opportunity as the modality expands across targets and earlier lines (ID: 60da32f29a76c304).